The differential ability of mRNA/saRNA vaccines to induce mucosal IgA responses in convalescent versus naïve subjects maybe due to boosting pre-existing mucosal resident B-cells generated during viral infection or primary vaccination via circulating antigen or migration of transduced cells from site of immunization39. This evidence concerns the gene CD79A and viral infectious disease.